Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

NCT ID: NCT03032510

Last Updated: 2022-01-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 1205 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-01-31
• Study Completion Date: 2018-01-31

Brief Summary

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

Detailed Description

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety and pharmacokinetics of eravacycline compared with ertapenem in the treatment of cUTI.

Randomization will be stratified based on two criteria: (1) by primary site of infection (pyelonephritis and normal urinary tract anatomy vs all other diagnoses) and (2) by the receipt of a single dose of effective non-study antibiotics for the acute cUTI within 72 hours prior to randomization. An enrollment cap of approximately 50% is planned for subjects with pyelonephritis with normal urinary tract anatomy. Also, an enrollment cap of approximately 20% is planned for subjects who have received a single dose of non-study antibiotics for the acute cUTI within 72 hours prior to randomization.

In this study subjects will be enrolled and randomized to one of two treatment arms in a 1:1 ratio: (i) eravacycline intravenously (IV) / levofloxacin (PO), or (ii) ertapenem (IV) / levofloxacin (PO).

Conditions

Complicated Urinary Tract Infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Eravacycline (Intravenous)/Levofloxacin (Oral)

Group Type: EXPERIMENTAL

Eravacycline

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Levofloxacin

Intervention Type: DRUG

Ertapenem (Intravenous)/Levofloxacin (Oral)

Group Type: ACTIVE_COMPARATOR

Ertapenem

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Levofloxacin

Intervention Type: DRUG

Interventions

Eravacycline

Intervention Type: DRUG

Ertapenem

Intervention Type: DRUG

Placebo

Intervention Type: DRUG

Levofloxacin

Intervention Type: DRUG

Other Intervention Names

TP-434; Invanz; Levaquin

Eligibility Criteria

Inclusion Criteria

1. Male or female participant with either:

1. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), or

2. cUTI with at least one of the following conditions associated with a risk for developing cUTI:

• Indwelling urinary catheter
• Urinary retention (at least approximately 100 milliliters (mL) of residual urine after voiding)
• History of neurogenic bladder
• Partial obstructive uropathy (for example, nephrolithiasis, bladder stones, and ureteral strictures)
• Azotemia of renal origin (not congestive heart failure [CHF] or volume related) such that the serum blood urea nitrogen [BUN] is elevated (>20 milligrams [mg]/deciliters [dL]) and the serum BUN:creatinine ratio is <15
• Surgically modified or abnormal urinary tract anatomy (for example, bladder diverticula, redundant urine collection system) except urinary tract surgery within the last 30 days (placing of stents or catheters is not considered to be surgical modification)

2. At least 18 years of age at time of consent

3. Able to provide informed consent

4. At least two of the following signs or symptoms:

1. Chills, rigors, or warmth associated with fever or hypothermia

2. Flank pain (pyelonephritis) or pelvic pain (cUTI)

3. Nausea or vomiting

4. Dysuria, urinary frequency, or urinary urgency

5. Costo-vertebral angle tenderness on physical examination

5. Urine specimen with evidence of pyuria

1. Dipstick analysis positive for leukocyte esterase (where positive result is at least "++" as indicated on the urine dipstick provided in the laboratory kit), or

2. ≥10 white blood cells (WBCs) per cubic millimeter, or

3. ≥10 WBCs per high power field

6. If male: must agree to use an effective barrier method of contraception (for example, condom) during the study and for 14 days following the last dose if sexually active with a female of childbearing potential

7. If female, not pregnant or nursing or, if of childbearing potential: must commit to either use at least two medically accepted, effective methods of birth control (for example, condom, spermicidal gel, oral contraceptive, indwelling intrauterine device, hormonal implant /patch, injections, approved cervical ring) during study drug dosing and for 14 days following last study drug dose or practicing sexual abstinence

Exclusion Criteria

1. Use of systemic antibiotics effective in cUTI within 72 hours prior to enrollment except under the following circumstances:

1. Participants with suspected acute cUTI who have received a single dose of effective non-study antibiotics for the acute cUTI

2. Signs and symptoms of cUTI developed while on the antibiotic for another indication

2. History of an ertapenem-resistant urinary tract infection within 1 year of enrollment

3. Likely to require >10 days of antibiotic treatment to cure the acute cUTI or likely to receive ongoing antibacterial drug prophylaxis prior to the Follow Up visit (21-28 days after randomization) [for example, participants with chronic vesiculo-ureteral reflux]

4. Unlikely to survive at least through the duration of the study

5. Hypotension, systolic blood pressure ≤90 millimeters of mercury [mmHg]

6. Complicated pyelonephritis with complete obstruction or known or suspected renal or perinephric abscess, emphysematous pyelonephritis, or Any condition likely to require surgery to achieve cure (this does not include procedure to place catheters or obtain diagnosis)

7. Known or suspected urinary fungal infection

8. Uncomplicated lower urinary tract infections

9. Suspected or confirmed active prostatitis, or currently under treatment for prostatitis

10. High risk for cUTI due to Pseudomonas (for example, history of prior cUTIs due to Pseudomonas, ≥20 mg once a day prednisone or equivalent steroid, and other risk factors as perceived by the Investigator)

11. History of renal transplantation

12. Presence of an ileal loop

13. Any history of trauma to the pelvis or urinary tract occurring within 30 days of screening

14. Indwelling urinary catheters present at screening which are not expected to be removed or replaced within 72 hours of enrollment (for example, nephrostomy tubes, stents, urethral and suprapubic catheters).

15. Known concomitant human immunodeficiency virus (HIV) infection with CD4 counts below 200 within the last six months, or an acquired immune deficiency syndrome (AIDS) defining diagnosis within the last six months

16. Neutropenia (Absolute neutrophil count <1,000 polymorphonuclear leukocytes [PMNs]/microliters [µL])

17. Participation in a study with an experimental drug or device within 30 days prior to enrollment

18. Known or suspected hypersensitivity to tetracyclines, carbapenems, or β-lactams

19. History of seizures

20. Any other unstable or clinically significant concurrent medical condition (for example, immunosuppressive therapy, chemotherapy, class IV heart or lung disease, end stage renal disease, or requiring hemodialysis) that would, in the opinion of the Investigator, jeopardize the safety of a participant and/or their compliance with the protocol

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tetraphase Pharmaceuticals, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Chief Medical Officer

Role: STUDY_DIRECTOR

Tetraphase Pharmaceuticals

Locations

Fullerton, California, United States

Los Angeles, California, United States

Torrance, California, United States

Coral Gables, Florida, United States

Doral, Florida, United States

Miami, Florida, United States

Columbus, Georgia, United States

St Louis, Missouri, United States

Las Vegas, Nevada, United States

Baytown, Texas, United States

Graz, , Austria

Linz, , Austria

Salzburg, , Austria

Pleven, , Bulgaria

Plovdiv, , Bulgaria

Razgrad, , Bulgaria

Rousse, , Bulgaria

Smyadovo, , Bulgaria

Sofia, , Bulgaria

Varna, , Bulgaria

Veliko Tarnovo, , Bulgaria

Tallinn, , Estonia

Tartu, , Estonia

Võru, , Estonia

K'ut'aisi, , Georgia

T'bilisi, , Georgia

Baja, , Hungary

Budapest, , Hungary

Miskolc, , Hungary

Nagykanizsa, , Hungary

Nyíregyháza, , Hungary

Sopron, , Hungary

Szentes, , Hungary

Tatabánya, , Hungary

Jelgava, , Latvia

Riga, , Latvia

Valmiera, , Latvia

Chisinau, , Moldova

Brasov, , Romania

Bucharest, , Romania

Craiova, , Romania

Oradea, , Romania

Arkhangelsk, , Russia

Moscow, , Russia

Pyatigorsk, , Russia

Rostov-on-the-Don, , Russia

Saint Petersburg, , Russia

Smolensk, , Russia

Vsevolozhsk, , Russia

Yaroslavl, , Russia

Nitra, , Slovakia

Poprad, , Slovakia

Prešov, , Slovakia

Svidník, , Slovakia

Žilina, , Slovakia

Chernihiv, , Ukraine

Chernivtsi, , Ukraine

Dnipro, , Ukraine

Ivano-Frankivsk, , Ukraine

Kharkiv, , Ukraine

Kyiv, , Ukraine

Lviv, , Ukraine

Mykolaiv, , Ukraine

Odesa, , Ukraine

Poltava, , Ukraine

Uzhhorod, , Ukraine

Vinnytsia, , Ukraine

Zaporizhia, , Ukraine

Zhytomyr, , Ukraine

Countries

United States; Austria; Bulgaria; Estonia; Georgia; Hungary; Latvia; Moldova; Romania; Russia; Slovakia; Ukraine

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

TP-434-021

Identifier Type: -

Identifier Source: org_study_id